177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy.

Sangeeta Ray BanerjeeVivek KumarAla LisokJian ChenIl MinnMary BrummetSrikanth BoinapallyMichael ColeEthel NgenBryan WharramCory BraytonRobert F HobbsMartin G Pomper

Published in: European journal of nuclear medicine and molecular imaging (2019)

177Lu-L1 is a viable clinical candidate for radionuclide therapy of PSMA-expressing malignancies because of its high tumor-targeting ability and low off-target radiotoxic effects.

Keyphrases

pet imaging
pet ct
cancer therapy
stem cells
drug delivery
mesenchymal stem cells
cell therapy
positron emission tomography